Research programme: Gram-negative infection cephems - Shionogi/GlaxoSmithKline

Drug Profile

Research programme: Gram-negative infection cephems - Shionogi/GlaxoSmithKline

Latest Information Update: 19 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Developer GlaxoSmithKline; Shionogi
  • Class Cephems
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gram-negative infections

Most Recent Events

  • 09 Nov 2015 Discontinued - Preclinical for Gram-negative infections in Japan (Parenteral)
  • 22 May 2012 A lead candidate enters into clinical development
  • 22 Mar 2012 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top